- Trials with a EudraCT protocol (80)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
80 result(s) found for: Transfusion reactions.
Displaying page 1 of 4.
EudraCT Number: 2012-002920-33 | Sponsor Protocol Number: CLI00076 | Start Date*: 2012-12-10 |
Sponsor Name:CERUS CORPORATION | ||
Full Title: A Randomized Controlled Study to Evaluate Efficacy and Safety of S-303 Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion | ||
Medical condition: Subjects with Thalassemia Major Requiring Chronic RBC Transfusion | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002622-39 | Sponsor Protocol Number: PEDFOI | Start Date*: 2015-11-18 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Experimental Study Protocol on Treatment with plasma transfusions in Patients affected by type VI Osteogenesis Imperfecta | |||||||||||||
Medical condition: type VI Osteogenesis Imperfecta | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000936-24 | Sponsor Protocol Number: SHINE-TRAUMA | Start Date*: 2019-05-02 | |||||||||||
Sponsor Name:Section for Transfusion Medicine, Capital Region Blood Bank, Copenhagen University Hospital | |||||||||||||
Full Title: Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in trauma patients with haemorrhagic shock induced endotheliopathy – a multicentre randomized, placebo-controlled, blinded, inv... | |||||||||||||
Medical condition: Shock-induced endotheliopathy in trauma patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003173-28 | Sponsor Protocol Number: 11112 | Start Date*: 2012-06-13 |
Sponsor Name:Helsinki University Hospital | ||
Full Title: Volume replacement therapy in cardiac surgery: effect on renal function. | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001867-22 | Sponsor Protocol Number: PRETIC | Start Date*: 2018-09-27 | |||||||||||
Sponsor Name:Banc de Sang i teixits | |||||||||||||
Full Title: TRANSFUSION OF RED BLOOD CELLS, TRANEXAMIC ACID AND FIBRINOGEN CONCENTRATE FOR SEVERE TRAUMA HEMORRHAGE AT PRE-HOSPITAL PHASE OF CARE. A PILOT TRIAL. | |||||||||||||
Medical condition: TREATMENT OF SEVERE TRAUMA HEMORRHAGE AT PRE-HOSPITAL PHASE OF CARE. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004439-22 | Sponsor Protocol Number: CHUBX2018/64 | Start Date*: 2020-03-12 | ||||||||||||||||
Sponsor Name:CHU de Bordeaux | ||||||||||||||||||
Full Title: TRAnexamic Acid for Preventing blood loss following a cesarean delivery in women with placenta pREVIA: a multicenter randomised, double blind placebo controlled trial (TRAAPrevia) | ||||||||||||||||||
Medical condition: Postpartum hemorrhage, placenta previa, prevention, blood loss, transfusion | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003978-16 | Sponsor Protocol Number: PRooF-iTH | Start Date*: 2015-01-22 | ||||||||||||||||
Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank | ||||||||||||||||||
Full Title: Pilot Randomized trial of Fibrinogen in Trauma Haemorrhage (PRooF-iTH). | ||||||||||||||||||
Medical condition: Trauma patients with ongoing haemorrhage | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001296-33 | Sponsor Protocol Number: COMBAT-COVID-19 | Start Date*: 2020-05-06 | ||||||||||||||||
Sponsor Name:Section for Transfusion Medicine, Capital Region Blood bank, Copenhagen University Hospital | ||||||||||||||||||
Full Title: Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-ini... | ||||||||||||||||||
Medical condition: COVID-19 induced respiratory failure | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002341-20 | Sponsor Protocol Number: PLAF1003 | Start Date*: 2008-07-10 |
Sponsor Name:Queen Charlotte's and Chelsea Hospital | ||
Full Title: Randomized controlled trial comparing the effect of carbetocin vs syntocinon and ergometrine on postpartum haemorrhage in patients undergoing elective caesarean section | ||
Medical condition: Clinical efficacy comparing ( 2 drugs) carbetocin Vs syntocinon and ergometrine | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003416-38 | Sponsor Protocol Number: TMP-0916_02 | Start Date*: 2018-04-05 | |||||||||||
Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) | |||||||||||||
Full Title: Randomised, open lable, active controlled clinical trial to demonstrate safety and efficacy of an i.v. administration of Polyglucoferron compared to i.v. Ferric Carboxymaltose and oral iron substit... | |||||||||||||
Medical condition: preoperative iron deficiency anaemia in patients with planned elective non-cardiac surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001829-11 | Sponsor Protocol Number: UoL001337 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: The Carboprost or Oxytocin Postpartum haemorrhage Effectiveness Study. Carboprost vs Oxytocin as the First Line Treatment of Primary Postpartum Haemorrhage; A phase IV, double-blind, double-dummy, ... | |||||||||||||
Medical condition: Primary postpartum haemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003235-30 | Sponsor Protocol Number: H9H-MC-JBAV | Start Date*: 2014-02-10 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes | |||||||||||||
Medical condition: Myelodysplastic Syndromes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004931-21 | Sponsor Protocol Number: BO42162 | Start Date*: 2020-10-26 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTUR... | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) HU (Completed) FR (Trial now transitioned) PL (Trial now transitioned) GR (Completed) PT (Trial now transitioned) BE (Completed) IE (Prematurely Ended) NL (Trial now transitioned) EE (Completed) LT (Trial now transitioned) IT (Prematurely Ended) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005486-14 | Sponsor Protocol Number: EPIC-19 | Start Date*: 2021-01-11 |
Sponsor Name:Wroclaw Medical University | ||
Full Title: Using of convalescent plasma in the treatment of COVID-19 patients with metabolomic and laboratory evaluation of the progress of plasma therapy | ||
Medical condition: Covid-19 (Coronavirus Disease 2019) – acute infectious disease of the respiratory system caused by SARS-CoV-2 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-000568-32 | Sponsor Protocol Number: CLLTX1 | Start Date*: 2017-11-07 | ||||||||||||||||
Sponsor Name:Universität Köln | ||||||||||||||||||
Full Title: Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation | ||||||||||||||||||
Medical condition: Patients with poor risk CLL and Richter`s transformation requiring an allogeneic stem cell transplantation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000597-26 | Sponsor Protocol Number: BO42161 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PA... | |||||||||||||
Medical condition: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) HU (Completed) CZ (Trial now transitioned) PT (Trial now transitioned) IE (Trial now transitioned) NL (Trial now transitioned) EE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003122-28 | Sponsor Protocol Number: ArgLepi-2006 | Start Date*: 2008-12-19 | |||||||||||
Sponsor Name:Heinrich-Heine-Universität Düsseldorf | |||||||||||||
Full Title: Argatroban versus Lepirudin in Critically Ill Patients | |||||||||||||
Medical condition: Critically ill patients are usually treated with heparin for anticoagulation. A serious complication of heparin therapy is heparin-induced thrombocytopenia type II (HIT). Patients with HIT have t... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003439-12 | Sponsor Protocol Number: TMP-0916_03 | Start Date*: 2018-02-19 | |||||||||||
Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer für Translationale Medizin und Pharmakologie (ITMP) | |||||||||||||
Full Title: Safety and efficacy of postoperative i.v. iron substitution with Polyglucoferron compared to Ferric Carboxymaltose and oral iron in patients with diagnosed iron deficiency who develop anaemia pre- ... | |||||||||||||
Medical condition: pre-operative iron deficiency in patients with planned elective surgery and pre-/post-operative iron deficiency anamia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004677-20 | Sponsor Protocol Number: Gemtax IV | Start Date*: 2006-03-17 |
Sponsor Name:University of Heidelberg, Klinikum Mannheim, Dep Surgery/Thoracical Oncology | ||
Full Title: Randomised Phase II/III Study on Sectional Single Agent Gemcitabine and Docetaxel Versus Carboplatine / Gemcitabine Doublet Therapy, both combined Cetuximab in the Treatment of Advanced NSCLC (Stag... | ||
Medical condition: Lung cancer remains the leading cause of cancer-related death in men and has increased its incidence in women over the past decades (protocol page 9). Data from both meta-analysis and clinical tria... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) LT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000452-28 | Sponsor Protocol Number: VIPER-OCTA | Start Date*: 2014-11-05 | |||||||||||
Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank | |||||||||||||
Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue – OCTAplas trial | |||||||||||||
Medical condition: patients undergoing emergency surgery for thoracic aortic dissections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
